Cost-effectiveness of vaccinating adults with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Germany.

Abstract

The introduction of routine infant vaccination against pneumococcal disease has resulted in a decreased overall invasive pneumococcal disease incidence in adults but also a change in invasive pneumococcal disease serotypes. This study aimed to assess the cost-effectiveness of 23-valent pneumococcal polysaccharide vaccine (PPV23) in Germany in this context… (More)
DOI: 10.1586/erp.12.54

Topics

Cite this paper

@article{Jiang2012CosteffectivenessOV, title={Cost-effectiveness of vaccinating adults with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Germany.}, author={Yiling Jiang and Aline Gauthier and Lieven Annemans and Mark van der Linden and Laurence Nicolas-Spony and Xavier Bresse}, journal={Expert review of pharmacoeconomics & outcomes research}, year={2012}, volume={12 5}, pages={645-60} }